Abstract: The present invention relates to an alpha-arteether resistance domain (ADR) of Sequence ID No.1 and a method of identifying ADR in alpha-arteether resistant pathogens and lastly, it relates to set three pairs of primers of sequence ID Nos. 3 to 8.

Abstract: The present invention relates to the development of a unique inflorescence bearing mutant plant type lli/lli (LEAF-LESS INFLORESCENCE). Further the present invention relates to the development of a unique inflorescence bearing mutant plant type lli/lli (LEAF-LESS INFLORESCENCE) through chemical mutagenesis The present invention relates to the development of a new and distinct plant type for floricultural usage. The new type is a monogenic Mendelian recessive stable mutant plant of Catharanthus roseus with a novel leafless inflorescence architecture with increased flower frequency. This distinct plant of Catharanthus roseus was developed through chemical mutagenesis followed by salt tolerance selection.

Abstract: The present invention relates to an alpha-arteether resistance domain (ADR) of Sequence ID No.1 and a method of identifying ADR in alpha-arteether resistant pathogens and lastly, it relates to set three pairs of primers of sequence ID Nos. 3 to 8.

Abstract: The present invention relates to a rapid, sensitive, simple, and cost-effective spectrophotometric method of detecting and quantifying mycolic acid in a mycolic acid-fuschin dye complex with absorbance maxima ranging between 490-500 nm in the presence of various test compounds, for screening mycolic acid biosynthesis inhibitors useful as anti-microbial agents and a diagnostic kit thereof comprising basic fuschin dye in the concentration ranging between 0.1-1.0 gm/100 ml, phenol and 95% ethanol in the ratio ranging between 1:4 to 2:1 (v/v), and phenol and distilled water in the ratio ranging between 1:14 to 1:25.

Abstract: A formulation useful in the treatment of drug resistant bacterial infections comprising an effective amount of thymol obtained from the plant Trachyspermum ammi, mint oil containing an appropriate amount of monoterpenes obtained from a hybrid of Mentha spicata and Mentha arvensis, and conventional additives. A method for producing the formulation by mixing the above ingredients and a method for the treatment of drug resistance in a patient by administration of a therapeutically effective amount of the formulation.

Abstract: The present invention relates a hexane bioactive fraction and obtained from the roots of an aromatic plant named Vetiveria zizanioides commonly found in India for inhibiting the growth of drug resistant bacterial infections in humans and animals; also relates to a pharmaceutical composition comprising the bioactive extract with other additives for inhibiting the growth of drug resistant bacterial infections in humans and animals and a process for the isolation of said bioactive extract

Abstract: The present invention relates a hexane bioactive fraction and obtained from the roots of an aromatic plant named Vetiveria zizanioides commonly found in India for inhibiting the growth of drug resistant bacterial infections in humans and animals; also relates to a pharmaceutical composition comprising the bioactive extract with other additives for inhibiting the growth of drug resistant bacterial infections in humans and animals and a process for the isolation of said bioactive extract

Abstract: The present invention relates to a rapid, sensitive, simple, and cost-effective spectrophotometric method of detecting and quantifying mycolic acid in a mycolic acid-fuschin dye complex with absorbance maxima ranging between 490-500 nm in the presence of various test compounds, for screening mycolic acid biosynthesis inhibitors useful as anti-microbial agents and a diagnostic kit thereof comprising basic fuschin dye in the concentration ranging between 0.1-1.0 gm/100 ml, phenol and 95% ethanol in the ratio ranging between 1:4 to 2:1 (v/v), and phenol and distilled water in the ratio ranging between 1:14 to 1:25.

Abstract: A formulation useful in the treatment of drug resistant bacterial infections comprising an effective amount of thymol obtained from the plant Trachyspermum ammi, mint oil containing an appropriate amount of monoterpenes obtained from a hybrid of Mentha spicata and Mentha arvensis, and conventional additives. A method for producing the formulation by mixing the above ingredients and a method for the treatment of drug resistance in a patient by administration of a therapeutically effective amount of the formulation.

Abstract: A formulation useful in the treatment of drug resistant bacterial infections comprising an effective amount of thymol obtained from the plant Trachyspermum ammi, mint oil containing an appropriate amount of monoterpenes obtained from a hybrid of Mentha spicata and Mentha arvensis, and conventional additives. A method for producing the formulation by mixing the above ingredients and a method for the treatment of drug resistance in a patient by administration of a therapeutically effective amount of the formulation.

Abstract: This invention is related to the development of strategic and novel composition comprising &agr; arteether and nalidixic acid or quinolone drugs, said composition useful as an advanced generation drug to counter the resistance development itself and having a potential to be used in treating infectious diseases and in inhibiting the resistance developed due to mutation in the gyr A gene of bacteria, particularly in those cases where drug resistant strains are known to appear very frequently.

Abstract: Novel formulation useful in the treatment of drug resistant bacterial infections comprising an effective amount of ‘Thymol’ obtained from the plant Trychyspermum ammi, combination of mint oil containing appropriate amounts of monoterpene obtained from Mentha spicata and Mentha arvensis and obtaining conventional additives, a method for producing the formulation by mixing the above ingredients and a method for the treatment of drug resistant in a patient by administration of a therapeutically effective amount of the said formulation.

Abstract: The present invention relates to use .alpha.-arteether as a antibacterial agent, preferably for gyr mutant bacteria which are resistant to quinolone drugs and can be used as therapeutic agents for treating drug resistant bacterial infections, and also as a antifungal agent.

Abstract: The present invention relates to the development of a unique inflorescence bearing mutant plant type lli/lli (LEAF-LESS INFLORESCENCE). Further the present invention relates to the development of a unique inflorescence bearing mutant plant type lli/lli (LEAF-LESS INFLORESCENCE) through chemical mutagenesis. The present invention relates to the development of a new and distinct plant type for floricultural usage. The new type is a monogenic Mendelian recessive stable mutant plant of Catharanthus roseus with a novel leafless inflorescence architecture with increased flower frequency. This distinct plant of Catharanthus roseus was developed through chemical mutagenesis followed by salt tolerance selection.